trial

Anti-Inflammatory Challenge in Schizophrenia

NCTId NCT05823532
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 60 (estimated)
Sponsored by Emory University
Primary completion 2028-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2024-04-18
Primary completion
2028-03
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Infliximab

Sponsors

Emory UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
David R Goldsmith, MDPrincipal Investigator

Sites

2 total
Atlanta, United StatesAtlanta, United States

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE4
Primary Completion Date
2028-03
Status
RECRUITING
relationships
The graph out of here
drug
Infliximab
drug
lead_sponsor
Emory University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Inflammation
indication
investigator
David R Goldsmith, MD
person